**Question:** Not seen in tumor lysis syndrome: September 2009

**Core Concept:**
Tumor lysis syndrome (TLS) is a potentially life-threatening complication that occurs in patients with rapidly dividing tumors, such as leukemia or lymphoma, when treatment with chemotherapy or radiotherapy induces the rapid death of cancer cells. This leads to the release of intracellular substances into the bloodstream, causing electrolyte imbalances, acidosis, renal dysfunction, and hyperuricemia.

**Why the Correct Answer is Right:**
The correct answer is **Option D:** "Anemia."

TLS is characterized by the release of intracellular contents into the bloodstream, which leads to the aforementioned complications. Anemia is not a feature of TLS as it is a condition resulting from a decrease in red blood cell mass or hemoglobin concentration, typically due to hemolysis, blood loss, or decreased production. While anemia could be a result of other causes in a patient with TLS, it is not directly associated with TLS itself.

**Why Each Wrong Option is Incorrect:**

**Option A (Leukocytosis):**
While leukocytosis is common in patients with acute leukemia, it is still not a defining feature of TLS. The main focus of TLS is the release of intracellular contents and the subsequent complications, rather than the initial increase in white blood cell count.

**Option B (Hyperkalemia):**
Hyperkalemia is a common electrolyte imbalance seen in TLS due to the release of potassium-rich intracellular contents. However, it is not specific to TLS and can be seen in other conditions as well.

**Option C (Hyperuricemia):**
Hyperuricemia is a common feature of TLS as the rapid cell death leads to increased levels of uric acid in the bloodstream. Though not the primary focus of TLS, hyperuricemia is still relevant in understanding the syndrome.

**Core Concept:**
TLS is a complex syndrome involving the release of intracellular contents from rapidly dividing tumor cells due to chemotherapy or radiotherapy. This leads to life-threatening complications that need urgent management.

**Why Each Wrong Option is Incorrect:**

**Option A (Leukocytosis):**
Leukocytosis is a common finding in patients with acute leukemia but is not specific to TLS. While it may occur in TLS due to increased tumor cell death, it is not the defining feature of the syndrome.

**Option B (Hyperkalemia):**
Hyperkalemia is a common electrolyte imbalance in TLS due to the release of potassium-rich intracellular contents. However, it is not specific to TLS and can occur in other conditions as well.

**Option C (Hyperuricemia):**
Hyperuricemia is a common feature of TLS, as increased tumor cell death leads to elevated uric acid levels in the bloodstream. Although hyperuricemia is not the primary focus of TLS, it is still relevant to understanding the syndrome.

**Core Concept:**
TLS is a serious complication of chemotherapy or radiotherapy in patients with rapidly dividing tumors, which requires prompt management.

**Why Each